[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608301":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":27,"collaborators":11,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":11,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":11,"enrollmentInfo":38,"targetDuration":11,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":11,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":11},{"fullName":5,"class":6},"SciNeuro","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SNP318","EXPERIMENTAL",null,[13],"Drug: SNP318",{"label":15,"type":16,"description":11,"interventionNames":17},"Matching Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Once daily, oral administration",[9],{"type":21,"name":25,"description":22,"armGroupLabels":26,"otherNames":11},"Placebo",[15],{"type":28,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100608301","phase-2-a-phase-2a-study-to-evaluate-the-safety-tolerability-and-efficacy-of-snp318-in-dme-patients-100608301",false,"NCT07199777","A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients","A Phase 2a, Randomized, Double-masked, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in Patients With Diabetic Macular Edema","Main Inclusion Criteria:\n\n1. Confirmed diabetes mellitus Type 1 or Type 2, with stable glycemic control\n2. Center-involved DME with CST \\>=320 µm (Study eye)\n3. BCVA between 82 and 25 letters, inclusive (Study eye)\n4. BCVA score ≥ 25 letters (Non-study eye)\n\nMain Exclusion Criteria:\n\n1\\. Use of the last intravitreal anti-VEGF injection in the study eye within 90 days prior to Screening","ALL","18 Years",{"count":39,"type":40},60,"ESTIMATED","INTERVENTIONAL",[43],"PHASE2","The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.",[46,47],"Diabetic Macular Edema","DME","NOT_YET_RECRUITING","2025-09-22",{"date":51,"type":52},"2025-09-30","ACTUAL",{"date":54,"type":40},"2025-11",{"date":56,"type":40},"2027-03",{"name":5,"class":6}]